INTRICON CORPORATION (NASDAQ:IIN) Files An 8-K Regulation FD Disclosure

Item 7.01Regulation FD Disclosure.

On February 17, 2017, IntriCon Corporation completed the sale of
the assets of its cardiac diagnostic monitoring business to
Datrix, LLC. Terms of the transaction include a four year
earn-out based on revenue thresholds.

About INTRICON CORPORATION (NASDAQ:IIN)

IntriCon Corporation is engaged in designing, developing, engineering, manufacturing and distributing body-worn devices. The Company operates through body-worn device segment. The Company serves the body-worn device market by designing, developing, engineering and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies, complete assemblies and software solutions, primarily for the value hearing health market, the medical bio-telemetry market and the professional audio communication market. The Company has facilities in Minnesota, California, Singapore, Indonesia, the United Kingdom and Germany, and operates through its subsidiaries. The Company’s product offering includes a hearing aid discount program for health plans. This program is available around the nation to health insurers, including employer-sponsored, individual and Medicare plans. The Company also has various international value hearing aid (VHA) initiatives.

INTRICON CORPORATION (NASDAQ:IIN) Recent Trading Information

INTRICON CORPORATION (NASDAQ:IIN) closed its last trading session down -0.15 at 7.55 with 12,382 shares trading hands.